Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11497814 Compositions and methods of treating muscle atrophy and myotonic dystrophy

Patent 11497814 was granted and assigned to Avidity Biosciences on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Avidity Biosciences

Current Assignee

Avidity Biosciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11497814

Date of Patent

November 15, 2022

Patent Application Number

17529197

Date Filed

November 17, 2021

Patent Citations

‌

US Patent 10881743 Compositions and methods of treating muscle atrophy and myotonic dystrophy

‌

US Patent 10000754 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

‌

US Patent 10487149 Nucleic acid-polypeptide compositions and uses thereof

‌

US Patent 10550188 Nucleic acid-polypeptide compositions and uses thereof

‌

US Patent 10787519 Nucleic acid-polypeptide compositions and uses thereof

‌

US Patent 11179472 Nucleic acid-polypeptide compositions and methods of inducing exon skipping

Patent Primary Examiner

‌

Kimberly Chong

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11497814 Compositions and methods of treating muscle atrophy and myotonic dystrophy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API